» Articles » PMID: 27019545

Potent P2X Receptor Antagonists: Tyrosyl Derivatives Synthesized Using a Sequential Parallel Synthetic Approach

Overview
Journal Drug Dev Res
Specialty Pharmacology
Date 2016 Mar 29
PMID 27019545
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Novel analogs of 1-(,-bis[5-isoquinolinesulfonyl]-N-methyl-L-tyrosyl)-4-phenylpiperazine (KN-62,1) were synthesized and found to be potent antagonists in a functional assay, inhibition of ATP-induced K efflux in HEK293 cells expressing recombinant human P2X receptors. Antagonism of murine P2X receptors was also observed. The analogs consisted of L-tyrosine derivatives, of the general structure R-Tyr(OR)-piperazinyl-R, in which three positions were systematically varied in structure through facile acylation reactions. Each of the three positions was optimized in sequence through parallel synthesis alternating with biological evaluation, leading to the identification and optimization of potent P2X antagonists. The optimal groups at R were found to be large hydrophobic groups, linked to the α-amino position through carbamate, amide, or sulfonamide groups. The benzyloxycarbonyl (Cbz) group was preferred over most sulfonamides and other acyl groups examined, except for quinoline sulfonyl. At R, an arylsulfonate ester was preferred, and the order of potency was p-tolyl, p-methoxyphenyl, phenyl > α-naphthyl, β-naphthyl. A benzoyl ester was of intermediate potency. Aliphatic esters and carbonate derivatives at the tyrosyl phenol were inactive, while a tyrosyl O-benzyl ether was relatively potent. The most potent P2X receptor antagonists identified in this study contained Cbz at the R position, an aryl sulfonate at the R position, and various acyl groups at the R position. At R, -butyloxycarbonyl- and benzoyl groups were preferred. The opening of the piperazinyl ring to an ethylene diamine moiety abolished antagonism. In concentration-response studies, a di-isoquinolinyl, Boc derivative, (MRS2306), displayed an IC value of 40 nM as an antagonist of P2X receptor-mediated ion flux and was more potent than the reference compound . N-Cbz, Boc-piperazinyl derivatives, (MRS2317), (MRS2326), and (MRS2409) were less potent than , with IC values of 200-300 nM.

Citing Articles

Oxidized ATP protection against anthrax lethal toxin.

Moayeri M, Wickliffe K, Wiggins J, Leppla S Infect Immun. 2006; 74(7):3707-14.

PMID: 16790743 PMC: 1489720. DOI: 10.1128/IAI.00051-06.


Functionalized congeners of tyrosine-based P2X(7) receptor antagonists: probing multiple sites for linking and dimerization.

Chen W, Ravi R, Kertesy S, Dubyak G, Jacobson K Bioconjug Chem. 2002; 13(5):1100-11.

PMID: 12236792 PMC: 5577561. DOI: 10.1021/bc020025i.

References
1.
Bringmann A, Pannicke T, Moll V, Milenkovic I, Faude F, Enzmann V . Upregulation of P2X(7) receptor currents in Müller glial cells during proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2001; 42(3):860-7. View

2.
Coutinho-Silva R, Persechini P, Bisaggio R, Perfettini J, Neto A, Kanellopoulos J . P2Z/P2X7 receptor-dependent apoptosis of dendritic cells. Am J Physiol. 1999; 276(5):C1139-47. DOI: 10.1152/ajpcell.1999.276.5.C1139. View

3.
Fredholm B, Abbracchio M, Burnstock G, Dubyak G, Harden T, Jacobson K . Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci. 1997; 18(3):79-82. PMC: 4460977. DOI: 10.1016/s0165-6147(96)01038-3. View

4.
Kim Y, de Zwart M, Chang L, Moro S, Von Frijtag Drabbe Kunzel J, Melman N . Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. J Med Chem. 1998; 41(15):2835-45. PMC: 11687614. DOI: 10.1021/jm980094b. View

5.
Ferrari D, Stroh C, Schulze-Osthoff K . P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. J Biol Chem. 1999; 274(19):13205-10. DOI: 10.1074/jbc.274.19.13205. View